Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
12
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
fda
biotech
drugs
san francisco blog main
alnylam pharmaceuticals
new york blog main
new york top stories
patisiran
san francisco top stories
akcea therapeutics
avapritinib
blueprint medicines
deals
hereditary transthyretin amyloidosis
inotersen
onpattro
rna interference
roche
san diego blog main
san diego top stories
tafamidis
cancer
eli lilly
europe blog main
europe top stories
european medicines agency
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
pfizer
postpartum depression
pralsetinib
What
fda
12
×
drug
medicine
approval
alnylam
rna
therapeutics
approved
blueprint
cancer
medicines
rnai
ago
approves
depression
filing
gene
historic
hits
interference
new
pharmaceuticals
phase
plans
puts
ret
roche
second
seek
specifically
therapy
type
uses
address
affects
afternoon
aldeyra
alnylam’s
americans
announced
Language
unset
Current search:
fda
×
boston
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision